Impact of Gender on Cardiovascular Outcome in Patients at Cardiovascular High Risk: Analysis of the Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET)

Study Questions:

Does gender independently impact cardiovascular (CV) risk?